The Size of the Europe Atopic Dermatitis Treatment Market size is valued at USD 3.14 billion in 2020 and is expected to grow at a CAGR of 13.6%, projected to reach USD 5.94 billion by 2025 during the forecast period 2020-2025.
Atopic Dermatitis is an inflammatory skin disease. The degree of its severity varies from patient to patient. It usually begins in childhood and is mostly confined to the flexural surfaces of the body. It is highly prevalent. It is more commonly known as eczema. Itching, redness of the skin, cracking, weeping, etc. are symptoms of it. It is a long term disease. Low humidity, cold weather, seasonal allergies are the common causes of it. A pattern of the disease and its severity determine the kind of treatment it ought to receive.
Growing patient population, a lot of new product launches, climate change, and large pipeline products are the primary drivers of market growth. Very strict regulations and generic competition are the primary restraints of market growth.
Europe Atopic Dermatitis Treatment Market has been segmented and sub-segmented into the following categories
On the basis of region, Europe is the second-largest market. Heavy investment in R&D activities in this region is the cause of the observable trend.
Prominent Companies leading the Europe Atopic Dermatitis Treatment Market Profiled in the Report are Astellas Pharma Inc., Valeant Pharmaceuticals International, Inc., and Sanofi S.A. Other players in the market include Anacor Pharmaceuticals, Inc. Meda Pharmaceuticals, Regeneron Pharmaceuticals Inc., and Novartis International AG, Pfizer Inc.,
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Treatment Type
5.1.1 Introduction
5.1.2 Drug Treatment
5.1.2.1 Emollients
5.1.2.2 Antihistamines
5.1.2.3 Antibiotics
5.1.2.4 Corticosteroids
5.1.2.5 Calcineurin Inhibitors
5.1.3 Radiation Treatment
5.1.4 Y-o-Y Growth Analysis, By Treatment Type
5.1.5 Market Attractiveness Analysis, By Treatment Type
5.1.6 Market Share Analysis, By Treatment Type
5.2 Route of administration
5.2.1 Introduction
5.2.2 Topical
5.2.3 Oral
5.2.4 Y-o-Y Growth Analysis, By Route of administration
5.2.5 Market Attractiveness Analysis, By Route of administration
5.2.6 Market Share Analysis, By Route of administration
5.3 Distribution Channel
5.3.1 Introduction
5.3.2 Hospital Pharmacies
5.3.3 Retail Pharmacies
5.3.4 Online Pharmacies
5.3.5 Y-o-Y Growth Analysis, By Distribution Channel
5.3.6 Market Attractiveness Analysis, By Distribution Channel
5.3.7 Market Share Analysis, By Distribution Channel
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Treatment Type
6.1.3.3 By Route of administration
6.1.3.4 By Distribution Channel
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Treatment Type
6.1.4.3 By Route of administration
6.1.4.4 By Distribution Channel
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Treatment Type
6.1.5.3 By Route of administration
6.1.5.4 By Distribution Channel
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Astellas Pharma Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Sanofi S.A.
8.3 Valeant Pharmaceuticals International, Inc.
8.4 Novartis International AG
8.5 Pfizer Inc.
8.6 Meda Pharmaceuticals
8.7 Regeneron Pharmaceuticals Inc.
8.8 Anacor Pharmaceuticals, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
